alexa Assessment of Bioavailability of Rifampicin as a Compon
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Assessment of Bioavailability of Rifampicin as a Component of Anti-tubercular Fixed Dose Combination Drugs Marketed in Pakistan.

Shahzad Hussain6* , Farnaz Malik1, Wajahat Mehmood2, Abdul Hameed3, Humanyun Riaz5 and Muhammad Rizwan4

1NIH, PAKISTAN

2DCTMD, NIH, Islamabad, Pakistan

3Menzies University, Australia

4QAU, Islamabad, Pakistan

5Punjab university, Lahore Pakistan

6Telemedicines Department, Holy Familly hospital, Rawalpindi, Pakistan

*Corresponding Author:
Shahzad Hussain
NIH, PAKISTAN
E-mail: [email protected]

Received Date: February 12, 2010; Accepted Date: May 12, 2010; Published Date: May 12, 2010

Citation: Hussain S, Malik F, Mehmood W, Hameed A, Riaz H, et al. (2010) Assessment of Bioavailability of Rifampicin as a Component of Anti-tubercular Fixed Dose Combination Drugs Marketed in Pakistan. J Bioequiv Availab 2: 067-071. doi: 10.4172/jbb.1000033

Copyright: © 2010 Hussain S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The World Health Organization (WHO) recommended DOTS program recommends treatment of TB with a combination of three to fi ve drugs. However, international bodies like the WHO and IUTLD (international union against tuberculosis and ling disease) recommend the use of only those fi xed dose combinations that have proven in vivo bioavailability. The present study was conducted to test the in vivo bioavailability of some of the formulations currently marketed in Pakistan on twenty six healthy volunteers as a three sequence, three period cross-over study. Rifampicin was administered in three different formulations out of which one (Formulation A) acted as a standard against which the other two formulations; Formulation B (Fixed dose combination without pyrazinamide) and formulation C (Fixed dose combination with pyrazinamide) were tested. Thirteen blood samples including a pre-dose sample were drawn over a period of 24 hours. Plasma samples were analyzed for rifampicin concentration by an HPLC method and critical pharmacokinetic parameters were calculated. Although, based on the con fi dence intervals for the ratios of geometric means of pharmacokinetic parameters none of the test formulations B or C could be declared bioequivalent, nevertheless effective formulations for the treatment of TB in Pakistan.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords